Bioton (WAR:BIO) Net Interest Margin (Bank Only) %

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WAR:BIO Bioton SA WAR:BIO
68 GF Score
Price zł3.83
GF Value zł4.75
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Bioton Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

WAR:BIO
68GF Score
Bioton SA WAR:BIO
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Bioton (WAR:BIO) Overvalued in 2026?

Based on GuruFocus' analysis, Bioton stock appears to be undervalued. The current stock price of zł3.83 is trading 19.4% below its estimated GF Value™ of zł4.75. GuruFocus considers Bioton to be Modestly Undervalued.

Key valuation signals for WAR:BIO:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: zł4.75 vs. price of zł3.83 (19.4% below fair value)
  • GF Score™: 68/100 with 3 warning signs

No single metric tells the full story. See the WAR:BIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bioton Business Description

Other Exchanges 7U5:Germany
Address Ul. Starościńska 5, Warszawa, POL, 02-516
Bioton SA is a Poland based company engaged in the principal business activity of manufacturing medicines and pharmaceutical preparations and production of pharmaceutical substances. The products of the company include recombinant human insulin in pharmaceutical substance form and as preparations for injections; glimepiride, an oral hypoglycemic drug; and metformin, an oral hypoglycemic drug. Its products line focuses on diet supplements, products for particular nutritional uses and cosmetics dedicated to patients with certain health problems. The group operates in Poland and internationally, of which majority of the revenue is derived from Poland.
68GF Score

Get the complete analysis for WAR:BIO

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł3.83
Price
zł4.75
GF Value